文献速递食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病消化道肿瘤与早癌

钾竞争性酸阻滞剂治疗酸相关疾病的综述

Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.
PubMed 文献 · Aliment Pharmacol Ther · 2021-02-16

本文综述了钾竞争性酸阻滞剂(P-CAB)的临床药理学与临床试验,检索至2020年11月。P-CAB抑酸比PPI更快更强;伏诺拉生愈合糜烂性食管炎非劣于兰索拉唑且维持缓解更优,伏诺拉生和替戈拉生愈合消化性溃疡非劣于兰索拉唑,基于伏诺拉生的幽门螺杆菌方案高效。

要点

  • P-CAB在临床相关剂量下抑酸比PPI更快速、更强。
  • 伏诺拉生愈合糜烂性食管炎非劣于兰索拉唑,维持缓解更优。
  • 伏诺拉生和替戈拉生愈合消化性溃疡非劣于兰索拉唑。

核心结论

  • P-CAB相比PPI具有一些潜在优势。
  • 多数研究在亚洲进行,美国和欧洲的临床试验结果预计2021年公布。

研究设计与样本

  • 综述,检索Medline(PubMed)、EMBASE、Web of Science和Cochrane Library从建库至2020年11月。
  • 纳入P-CAB临床药理学研究及已上市或在研药物的相关临床试验。

主要发现

  • 多数文献关于伏诺拉生,构成本综述主体。
  • 临床相关剂量下P-CAB对胃内酸度的抑制比PPI更快速和更强。
  • 伏诺拉生愈合糜烂性食管炎非劣于兰索拉唑(2项RCT,1137例),维持缓解更优(1项RCT,607例)。
  • 伏诺拉生和替戈拉生愈合消化性溃疡非劣于兰索拉唑(2项RCT,共1120例)。
  • 基于伏诺拉生的三联或二联方案对幽门螺杆菌感染高度有效。

关键数值与推荐

  • 伏诺拉生愈合糜烂性食管炎非劣于兰索拉唑:2项RCT,1137例。
  • 伏诺拉生维持糜烂性食管炎缓解优于兰索拉唑:1项RCT,607例。
  • 伏诺拉生和替戈拉生愈合消化性溃疡非劣于兰索拉唑:2项RCT,共1120例。

临床怎么用

  • P-CAB可用于酸相关疾病,抑酸起效快且强。
  • 伏诺拉生可用于糜烂性食管炎愈合和维持缓解。
  • 伏诺拉生或替戈拉生可用于消化性溃疡愈合。
  • 基于伏诺拉生的方案可用于幽门螺杆菌感染。

局限性

  • 多数研究在亚洲进行,欧美数据待公布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Potassium-competitive acid blockers (P-CABs) are a novel group of acid-suppressing medicines for the management of acid-related disorders. AIMS: To review published clinical pharmacology studies and clinical trials of P-CABs. METHODS: We conducted a comprehensive literature search including Medline (PubMed), EMBASE, Web of Science and the Cochrane Library from inception until November 2020, for studies of the clinical pharmacology of P-CABs and relevant clinical trials of those that are currently licensed or in development. RESULTS: Most publications concerned vonoprazan, which forms the bulk of this review. It is currently licensed in some Asian and South American countries and is being developed for North America. In clinically relevant doses, P-CABs have produced more rapid and profound suppression of intragastric acidity than proton pump inhibitors (PPIs). Vonoprazan was non-inferior to lansoprazole in healing erosive oesophagitis (2 randomised controlled trials [RCTs] in 1137 subjects) and superior in maintaining remission (1 RCT; 607 subjects). In 2 RCTs (1120 total subjects), both vonoprazan and tegoprazan were non-inferior to lansoprazole for healing peptic ulcers. Three RCTs and numerous non-randomised studies have compared vonoprazan-based and PPI-based regimens for Helicobacter pylori infection; vonoprazan-based triple or dual regimens have been highly effective. CONCLUSIONS: P-CABs have some potential advantages over PPIs. To date, most research has been conducted in Asia; results of clinical trials that are underway in the United States and Europe are anticipated in 2021.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Abdel-Aziz Y, Metz DC, Howden CW, et al. Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther. 2021. PMID: 33592125. doi:10.1111/apt.16295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。